Skip to main content
SpringerLink
Log in

Cinacalcet Hydrochloride

A Viewpoint by Sharon M. Moe

  • Adis Drug Profile
  • Guest Commentary
  • Published:
Drugs Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Block GA, Hulbert-Shearon TE, Levin NW, et al. Association of serum phosphorous and calcium × phosphorous product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis 1998; 31(4): 607–17

    Article  PubMed  CAS  Google Scholar 

  2. Chertow GM, Burke SK, Raggi P. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 2002; 64: 245–52

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Indiana University School of Medicine, Indianapolis, Indiana, USA

    Sharon M. Moe

Authors
  1. Sharon M. Moe
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Moe, S.M. Cinacalcet Hydrochloride. Drugs 65, 282 (2005). https://doi.org/10.2165/00003495-200565020-00008

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-200565020-00008

Search

Navigation